Developer docs
API playgroundTry for free, no card

Search company profiles

Sirona Dx

Full company profile

uuid000bpmn

Namestring
Sirona Dx
Legal namestring
Sirona Dx
Websiteurl
sironadx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Sirona Dx is a privately held, CLIA- and GCLP-accredited technical contract research organization (CRO) founded in 2016 and headquartered in a single Portland, Oregon laboratory (4640 SW Macadam Avenue). It is purpose-built to serve pharmaceutical and biotechnology sponsors developing immunotherapies and targeted therapies, providing specialized single-cell proteomics, transcriptomics, and spatial biology services from exploratory biomarker discovery through clinical trial laboratory support. The company serves 30 or more pharma and biotech clients with a consultative, enterprise sales motion that spans platform selection, custom panel design, assay optimization, validation, and bioinformatics analysis.

The company's core technology stack is platform-agnostic and multi-vendor, integrating Imaging Mass Cytometry (Fluidigm Hyperion), CyTOF mass cytometry, Akoya CODEX, Lunaphore COMET, NanoString CosMx and nCounter, Cytek full spectrum flow cytometry, Olink proximity extension assays, and Hamamatsu MoxiePlex imaging. Sirona Dx layers proprietary assay IP on top of these platforms, most notably a 34-marker Human Immune Portrait TME Panel for tumor microenvironment profiling and custom CyTOF panels reaching up to 45 markers. It augments wet-lab capabilities with AI-driven analytics via partnerships with PredxBio (SpaceIQ), Nucleai, and Scailyte (ScaiVision), and provides in-house bioinformatics and digital image analysis.

The business model is straightforward professional services: revenue is generated through contracted laboratory and analysis engagements with pharma, biotech, and academic medical center sponsors, priced via contact-based quoting rather than published rates. Marketing relies on technical content, conference presence (e.g., AACR booth #3442), press release distribution, and a science portal. The company was awarded Medhealth Outlook's "Top 10 CRO of 2021," and has established strategic alliances with most leading spatial biology platform developers, positioning it as a category-leading specialty CRO for immunotherapy biomarker programs.

Short descriptiontext

Sirona Dx is a CLIA/GCLP-accredited technical CRO founded in 2016 in Portland, Oregon, providing spatial biology and single-cell multi-omics services to 30+ pharmaceutical and biotechnology clients developing immunotherapies and targeted therapies. It operates a multi-platform laboratory spanning Imaging Mass Cytometry, CyTOF, CODEX, COMET, and CosMx with custom assay development, bioinformatics, and AI-driven analytics partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPortland, United States
HQ citystring
Portland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology CRO, single cell multi-omics services, mass cytometry analysis, imaging mass cytometry, immunotherapy biomarker assays
Industry3 codes
PRIMARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Contract Research Services — Spatial Biology & Multi-Omics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Sirona Dx operates as a technical CRO providing specialized laboratory services to pharmaceutical and biotech companies. Revenue is generated through service contracts for single cell multi-omics, spatial biology, and biomarker analysis services. From exploratory biomarker development through to clinical trial support, services are provided across the drug development continuum.

sironadx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Human Immune Portrait TME Panel
Description

A 34-marker highly optimized IMC panel enabling comprehensive analysis of the tumor microenvironment at sub-cellular resolution.

sironadx.com
Core offering1 text field

Sirona Dx is a technical Contract Research Organization that provides spatial biology and single cell multi-omics laboratory services to pharmaceutical and biotechnology companies developing immuno-oncology and immune-based therapeutics. Its offerings span CyTOF/mass cytometry, imaging mass cytometry, multiplex immunofluorescence, spatial transcriptomics, histopathology and immune profiling, delivered through a CLIA/GCLP-accredited laboratory supported by bioinformatics analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Highly optimized 34 marker Immune Portrait TME Panel for comprehensive tumor microenvironment analysis at sub-cellular resolution
+3 more records
Product overview1 text field

Sirona Dx is a technical CRO founded in 2016, offering specialized single cell multi-omics and spatial biology services within a GCLP and CLIA accredited laboratory. The company's service portfolio centers on spatial biology platforms (including Nanostring CosMx, Fluidigm Hyperion/Imaging Mass Cytometry, Lunaphore COMET, and Akoya CODEX), CyTOF/mass cytometry for ultra-deep immunophenotyping up to 45 markers, Cytek full spectrum flow cytometry, and bulk cell analysis including Olink protein detection and NanoString nCounter gene expression. Core services include immune profiling, imaging mass cytometry, histopathology, IO expression assays, and advanced bioinformatics for digital image analysis and spatial data interpretation. Partnerships augment capabilities with AI-powered analytics platforms including PredxBio SpaceIQ, Nucleai, and Scailyte ScaiVision for biomarker discovery and predictive analytics.

Product and service8 records
1Spatial Biology Services
CategorySpatial Biology / Tissue Multi-Omics
Description

CRO service that characterizes tissue samples using spatial biology platforms to map cellular phenotypes and biomarker localization, supporting translational research for pharma and biotech sponsors.

2CyTOF / Mass Cytometry Services
CategorySingle-Cell Multi-Omics
Description

Fee-for-service high-parameter suspension mass cytometry using CyTOF instrumentation, enabling deep immune-phenotyping of cell populations from client-supplied samples.

3Imaging Mass Cytometry Services
CategorySpatial Biology / Tissue Multi-Omics
Description

Tissue-based multiplexed antibody imaging service using Imaging Mass Cytometry, allowing highly multiplexed spatial phenotyping of solid tumor and tissue specimens.

4Multiplex Immunofluorescence Services
CategoryTissue Multi-Omics / Immuno-Oncology
Description

Multiplex fluorescence-based tissue phenotyping service for simultaneous detection of multiple immune and tumor markers in formalin-fixed specimens.

5Immune Profiling Services
CategoryImmuno-Oncology / Translational Research
Description

Phenotypic and functional characterization of immune cell populations using multi-omics assays to support immunotherapy and cell-therapy development.

6IO Expression Assays
CategoryImmuno-Oncology / Biomarker Assays
Description

Immuno-oncology focused expression-based assays measuring immune-checkpoint and immune-signature biomarkers, available as a service offering for sponsors.

7Histopathology Services
CategoryHistopathology / Clinical-Grade Tissue Analytics
Description

Tissue processing, staining (including IHC and multiplexed IF) and histopathology read-outs delivered within a CLIA/GCLP-accredited laboratory environment.

8Bioinformatics and Data Analysis Services
CategoryBioinformatics / Data Analytics
Description

Downstream analytics, including image segmentation, cell phenotyping, clustering and biomarker interpretation, delivered alongside Sirona Dx's laboratory assays.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-15
Description

Strategic partnership to deliver integrated spatial proteomics solution for pharmaceutical companies. Sirona Dx leads assay design, development and validation while Nucleai provides AI-powered spatial analytics from feature extraction through biomarker discovery. Delivers seamless end-to-end solution from tissue data to biological insight for pharma sponsors.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-11
Description

Sirona Dx named as Technology Access Partner for Hamamatsu's MoxiePlex spatial proteomics technology. Partnership streamlines technology evaluation by providing customers access to spatial biology expertise within GCLP/CLIA accredited laboratory. Removes barriers to adoption through expertise in sample preparation, staining, imaging and bioinformatics analysis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-02
Description

Strategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ platform to unlock potential of genomic, proteomic and transcriptomic data. Sirona Dx serves as CRO partner facilitating deployment of Explainable AI-based diagnostic algorithms. Combined capabilities aim to identify novel spatial signatures in high-plex assays predicting therapy responses.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2023-09-08
Description

Integrated CosMx spatial molecular imaging platform. NanoString partners with Sirona Dx along with Macrogen and Propath to accelerate access to spatial biology capabilities for biopharma companies globally.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-23
Description

Sirona Dx became first US-based CRO to offer Lunaphore's COMET spatial biology platform as a service. COMET provides fully automated, high-throughput hyperplex tissue profiling with 40 markers per run. Partnership complements Sirona Dx's spatial-omics operations with off-the-shelf, label-free primary antibody compatibility.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-07-11
Description

Strategic partnership creating biomarker discovery engine combining Sirona Dx laboratory workflow solutions with Scailyte's AI-driven data analytics platform ScaiVision. Focus on oncology and immunology applications including patient qualification, stratification for clinical trials, and advanced therapy development.

Strategic tierKeyTypeGTM or Marketing PartnerAnnounced on2022-03-15
Description

Co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions. Ultivue's InSituPlex technology (up to 12-plex) complements Sirona Dx's high-parameter capabilities. Joint offering provides seamless workflow for biomarker discovery and drug development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-12-01
Description

Added CODEX ultra-high plex imaging platform to service offerings. Allows imaging of 40+ protein biomarkers across whole tissue sections. Provides multidimensional phenotypic maps of tumor microenvironment with single-cell resolution while maintaining spatial context.

9Fluidigm (Standard BioTools)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-11-01
Description

Sirona Dx launched Imaging Mass Cytometry services on Fluidigm Hyperion Imaging System. First Imaging Mass Cytometry CRO partner in the United States. Enables simultaneous imaging of up to 37 protein markers at subcellular resolution for biomarker discovery.

sironadx.com
Strategic tierKeyTypeTechnology or IntegrationAnnounced on2018-10-30
Description

Launched Oncocyst PD-L1 assay using IncellDx technology for bladder cancer detection. Detects and quantifies abnormal bladder cells and immune cells expressing PD-L1 from urine cytology specimens using multi-parameter flow cytometry and bioinformatics.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2016-11-10
Description

Adopted Thermo Fisher's Oncomine Focus Assay to run on Ion PGM System. Expands drug development and NGS services with 52 solid tumor genes associated with current oncology therapies.

Strategic tierKeyTypeTechnology or Integration
Description

Sirona Dx is an Olink Certified Service Provider using Olink technology for simultaneous measurement of hundreds of protein biomarkers from minimal sample volumes with exceptional sensitivity and specificity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Top-five global CRO with laboratory services and biomarker capabilities supporting clinical development. Comparable as a large-scale clinical trial services competitor; less specialized in spatial biology than Sirona Dx.

TypeBroad incumbent
Description

Joint venture central laboratory and biomarker services provider serving global clinical trials with flow cytometry, genomics, and immunoassay capabilities. Comparable as a clinical-trial-grade lab services competitor with overlapping biomarker offerings.

TypeDirect peer
Description

Specialized bioanalytical and biomarker CRO with deep large-molecule, immunoassay, and cell-based assay expertise serving global biopharma. Highly comparable to Sirona Dx as a focused, science-led CRO competing for biomarker and immuno-oncology work, though BioAgilytix is much larger and broader in scope.

TypeBroad incumbent
Description

Global lab services conglomerate with extensive pharma services including biomarker, genomic, and specialty assay work. Comparable as a scale player in pharma lab services with significant overlap in customer base, though Eurofins' reach is far broader.

TypeDirect peer
Description

Precision medicine-focused CRO with biomarker, immuno-oncology, and companion diagnostic development capabilities for biopharma. Comparable as a specialized services provider targeting the same pharma translational and clinical trial customer set.

TypeBroad incumbent
Description

One of the largest global CROs with central laboratory, biomarker, and specialty testing services including flow cytometry and genomic profiling. Competes with Sirona Dx for pharma biomarker contracts, though Labcorp's portfolio is far broader and lacks Sirona's pure-play spatial biology focus.

TypeDirect peer
Description

Specialized immunology and single-cell flow cytometry/mass cytometry CRO serving pharma biomarker discovery and clinical trials. Most directly comparable peer given its positioning as a premium scientific CRO focused on immune monitoring and multiplexed proteomics.

TypeBroad incumbent
Description

Clinical oncology-focused lab services company with growing pharma services division offering spatial biology and molecular profiling. Competes with Sirona Dx for biomarker work but operates at substantially larger scale and serves clinical diagnostics customers as well.

TypeBroad incumbent
Description

Major CRO with discovery, safety assessment, and specialty lab services including biomarker and cell-based assay work. Comparable customer overlap with Sirona Dx but a much broader services portfolio and global footprint.

TypeEmerging player
Description

Leading single-cell and spatial biology platform vendor (Chromium, Visium, Xenium) whose services partner ecosystem and direct-to-pharma support competes for the same single-cell/spatial work Sirona Dx services. Treated as an emerging player in services given its primary identity as a tool vendor, but increasingly adjacent to Sirona's offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sirona Dx

Contract Research Services — Spatial Biology & Multi-Omicssironadx.com

Sirona Dx is a CLIA/GCLP-accredited technical CRO founded in 2016 in Portland, Oregon, providing spatial biology and single-cell multi-omics services to 30+ pharmaceutical and biotechnology clients developing immunotherapies and targeted therapies. It operates a multi-platform laboratory spanning Imaging Mass Cytometry, CyTOF, CODEX, COMET, and CosMx with custom assay development, bioinformatics, and AI-driven analytics partnerships.

What Sirona Dx does

Sirona Dx is a privately held, CLIA- and GCLP-accredited technical contract research organization (CRO) founded in 2016 and headquartered in a single Portland, Oregon laboratory (4640 SW Macadam Avenue). It is purpose-built to serve pharmaceutical and biotechnology sponsors developing immunotherapies and targeted therapies, providing specialized single-cell proteomics, transcriptomics, and spatial biology services from exploratory biomarker discovery through clinical trial laboratory support. The company serves 30 or more pharma and biotech clients with a consultative, enterprise sales motion that spans platform selection, custom panel design, assay optimization, validation, and bioinformatics analysis.

The company's core technology stack is platform-agnostic and multi-vendor, integrating Imaging Mass Cytometry (Fluidigm Hyperion), CyTOF mass cytometry, Akoya CODEX, Lunaphore COMET, NanoString CosMx and nCounter, Cytek full spectrum flow cytometry, Olink proximity extension assays, and Hamamatsu MoxiePlex imaging. Sirona Dx layers proprietary assay IP on top of these platforms, most notably a 34-marker Human Immune Portrait TME Panel for tumor microenvironment profiling and custom CyTOF panels reaching up to 45 markers. It augments wet-lab capabilities with AI-driven analytics via partnerships with PredxBio (SpaceIQ), Nucleai, and Scailyte (ScaiVision), and provides in-house bioinformatics and digital image analysis.

The business model is straightforward professional services: revenue is generated through contracted laboratory and analysis engagements with pharma, biotech, and academic medical center sponsors, priced via contact-based quoting rather than published rates. Marketing relies on technical content, conference presence (e.g., AACR booth #3442), press release distribution, and a science portal. The company was awarded Medhealth Outlook's "Top 10 CRO of 2021," and has established strategic alliances with most leading spatial biology platform developers, positioning it as a category-leading specialty CRO for immunotherapy biomarker programs.

Sirona Dx firmographics

Firmographics
Name
Sirona Dx
Legal name
Sirona Dx
Website
https://sironadx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Sirona Dx is a CLIA/GCLP-accredited technical CRO founded in 2016 in Portland, Oregon, providing spatial biology and single-cell multi-omics services to 30+ pharmaceutical and biotechnology clients developing immunotherapies and targeted therapies. It operates a multi-platform laboratory spanning Imaging Mass Cytometry, CyTOF, CODEX, COMET, and CosMx with custom assay development, bioinformatics, and AI-driven analytics partnerships.
Ownership category
akta.pro rank

Sirona Dx industry classification

Industry
Product category
Contract Research Services — Spatial Biology & Multi-Omics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Spatial biology CRO
  • Single cell multi-omics services
  • Mass cytometry analysis
  • Imaging mass cytometry
  • Immunotherapy biomarker assays

Where Sirona Dx is headquartered

Location

Headquarters

HQ city
Portland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sirona Dx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Sirona Dx operates as a technical CRO providing specialized laboratory services to pharmaceutical and biotech companies. Revenue is generated through service contracts for single cell multi-omics, spatial biology, and biomarker analysis services. From exploratory biomarker development through to clinical trial support, services are provided across the drug development continuum.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Sirona Dx product offering

Product offering

Core offering

Sirona Dx is a technical Contract Research Organization that provides spatial biology and single cell multi-omics laboratory services to pharmaceutical and biotechnology companies developing immuno-oncology and immune-based therapeutics. Its offerings span CyTOF/mass cytometry, imaging mass cytometry, multiplex immunofluorescence, spatial transcriptomics, histopathology and immune profiling, delivered through a CLIA/GCLP-accredited laboratory supported by bioinformatics analysis.

Product overview

Sirona Dx is a technical CRO founded in 2016, offering specialized single cell multi-omics and spatial biology services within a GCLP and CLIA accredited laboratory. The company's service portfolio centers on spatial biology platforms (including Nanostring CosMx, Fluidigm Hyperion/Imaging Mass Cytometry, Lunaphore COMET, and Akoya CODEX), CyTOF/mass cytometry for ultra-deep immunophenotyping up to 45 markers, Cytek full spectrum flow cytometry, and bulk cell analysis including Olink protein detection and NanoString nCounter gene expression. Core services include immune profiling, imaging mass cytometry, histopathology, IO expression assays, and advanced bioinformatics for digital image analysis and spatial data interpretation. Partnerships augment capabilities with AI-powered analytics platforms including PredxBio SpaceIQ, Nucleai, and Scailyte ScaiVision for biomarker discovery and predictive analytics.

Differentiator

Problem solved

Functional benefit

Brands

  • Human Immune Portrait TME Panel: A 34-marker highly optimized IMC panel enabling comprehensive analysis of the tumor microenvironment at sub-cellular resolution.

Products and services

  • Spatial Biology Services CRO service that characterizes tissue samples using spatial biology platforms to map cellular phenotypes and biomarker localization, supporting translational research for pharma and biotech sponsors.
  • CyTOF / Mass Cytometry Services Fee-for-service high-parameter suspension mass cytometry using CyTOF instrumentation, enabling deep immune-phenotyping of cell populations from client-supplied samples.
  • Imaging Mass Cytometry Services Tissue-based multiplexed antibody imaging service using Imaging Mass Cytometry, allowing highly multiplexed spatial phenotyping of solid tumor and tissue specimens.
  • Multiplex Immunofluorescence Services Multiplex fluorescence-based tissue phenotyping service for simultaneous detection of multiple immune and tumor markers in formalin-fixed specimens.
  • Immune Profiling Services Phenotypic and functional characterization of immune cell populations using multi-omics assays to support immunotherapy and cell-therapy development.
  • IO Expression Assays Immuno-oncology focused expression-based assays measuring immune-checkpoint and immune-signature biomarkers, available as a service offering for sponsors.
  • Histopathology Services Tissue processing, staining (including IHC and multiplexed IF) and histopathology read-outs delivered within a CLIA/GCLP-accredited laboratory environment.
  • Bioinformatics and Data Analysis Services Downstream analytics, including image segmentation, cell phenotyping, clustering and biomarker interpretation, delivered alongside Sirona Dx's laboratory assays.

Quantifiable outcome

  • Highly optimized 34 marker Immune Portrait TME Panel for comprehensive tumor microenvironment analysis at sub-cellular resolution
  • +3 more outcomes

Companies that use Sirona Dx

Customer profile

Segments3 records

Ideal customer profiles3 records

Sirona Dx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Sirona Dx partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and key.

  • NucleaicoreTechnology or Integration · 15 April 2026Strategic partnership to deliver integrated spatial proteomics solution for pharmaceutical companies. Sirona Dx leads assay design, development and validation while Nucleai provides AI-powered spatial analytics from feature extraction through biomarker discovery. Delivers seamless end-to-end solution from tissue data to biological insight for pharma sponsors.
  • Hamamatsu PhotonicscoreTechnology or Integration · 11 April 2025Sirona Dx named as Technology Access Partner for Hamamatsu's MoxiePlex spatial proteomics technology. Partnership streamlines technology evaluation by providing customers access to spatial biology expertise within GCLP/CLIA accredited laboratory. Removes barriers to adoption through expertise in sample preparation, staining, imaging and bioinformatics analysis.
  • PredxBiocoreStrategic or Co-development Partner · 2 April 2024Strategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ platform to unlock potential of genomic, proteomic and transcriptomic data. Sirona Dx serves as CRO partner facilitating deployment of Explainable AI-based diagnostic algorithms. Combined capabilities aim to identify novel spatial signatures in high-plex assays predicting therapy responses.
  • NanoString TechnologieskeyTechnology or Integration · 8 September 2023Integrated CosMx spatial molecular imaging platform. NanoString partners with Sirona Dx along with Macrogen and Propath to accelerate access to spatial biology capabilities for biopharma companies globally.
  • LunaphorecoreTechnology or Integration · 23 February 2023Sirona Dx became first US-based CRO to offer Lunaphore's COMET spatial biology platform as a service. COMET provides fully automated, high-throughput hyperplex tissue profiling with 40 markers per run. Partnership complements Sirona Dx's spatial-omics operations with off-the-shelf, label-free primary antibody compatibility.
  • ScailytekeyStrategic or Co-development Partner · 11 July 2022Strategic partnership creating biomarker discovery engine combining Sirona Dx laboratory workflow solutions with Scailyte's AI-driven data analytics platform ScaiVision. Focus on oncology and immunology applications including patient qualification, stratification for clinical trials, and advanced therapy development.
  • UltivuekeyGTM or Marketing Partner · 15 March 2022Co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions. Ultivue's InSituPlex technology (up to 12-plex) complements Sirona Dx's high-parameter capabilities. Joint offering provides seamless workflow for biomarker discovery and drug development.
  • Akoya BiosciencescoreTechnology or Integration · 1 December 2020Added CODEX ultra-high plex imaging platform to service offerings. Allows imaging of 40+ protein biomarkers across whole tissue sections. Provides multidimensional phenotypic maps of tumor microenvironment with single-cell resolution while maintaining spatial context.
  • Fluidigm (Standard BioTools)coreTechnology or Integration · 1 November 2018Sirona Dx launched Imaging Mass Cytometry services on Fluidigm Hyperion Imaging System. First Imaging Mass Cytometry CRO partner in the United States. Enables simultaneous imaging of up to 37 protein markers at subcellular resolution for biomarker discovery.
  • IncellDxkeyTechnology or Integration · 30 October 2018Launched Oncocyst PD-L1 assay using IncellDx technology for bladder cancer detection. Detects and quantifies abnormal bladder cells and immune cells expressing PD-L1 from urine cytology specimens using multi-parameter flow cytometry and bioinformatics.
  • Thermo Fisher ScientifickeyTechnology or Integration · 10 November 2016Adopted Thermo Fisher's Oncomine Focus Assay to run on Ion PGM System. Expands drug development and NGS services with 52 solid tumor genes associated with current oncology therapies.
  • OlinkkeyTechnology or IntegrationSirona Dx is an Olink Certified Service Provider using Olink technology for simultaneous measurement of hundreds of protein biomarkers from minimal sample volumes with exceptional sensitivity and specificity.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Sirona Dx competitors and assessment

Company assessment

Broad incumbents

  • ICON plc: Top-five global CRO with laboratory services and biomarker capabilities supporting clinical development. Comparable as a large-scale clinical trial services competitor; less specialized in spatial biology than Sirona Dx.
  • Q² Solutions: Joint venture central laboratory and biomarker services provider serving global clinical trials with flow cytometry, genomics, and immunoassay capabilities. Comparable as a clinical-trial-grade lab services competitor with overlapping biomarker offerings.
  • Eurofins Scientific: Global lab services conglomerate with extensive pharma services including biomarker, genomic, and specialty assay work. Comparable as a scale player in pharma lab services with significant overlap in customer base, though Eurofins' reach is far broader.
  • Labcorp Drug Development: One of the largest global CROs with central laboratory, biomarker, and specialty testing services including flow cytometry and genomic profiling. Competes with Sirona Dx for pharma biomarker contracts, though Labcorp's portfolio is far broader and lacks Sirona's pure-play spatial biology focus.
  • NeoGenomics Laboratories: Clinical oncology-focused lab services company with growing pharma services division offering spatial biology and molecular profiling. Competes with Sirona Dx for biomarker work but operates at substantially larger scale and serves clinical diagnostics customers as well.
  • Charles River Laboratories: Major CRO with discovery, safety assessment, and specialty lab services including biomarker and cell-based assay work. Comparable customer overlap with Sirona Dx but a much broader services portfolio and global footprint.

Direct peers

  • BioAgilytix Labs: Specialized bioanalytical and biomarker CRO with deep large-molecule, immunoassay, and cell-based assay expertise serving global biopharma. Highly comparable to Sirona Dx as a focused, science-led CRO competing for biomarker and immuno-oncology work, though BioAgilytix is much larger and broader in scope.
  • Precision for Medicine: Precision medicine-focused CRO with biomarker, immuno-oncology, and companion diagnostic development capabilities for biopharma. Comparable as a specialized services provider targeting the same pharma translational and clinical trial customer set.
  • CellCarta (formerly Caprion): Specialized immunology and single-cell flow cytometry/mass cytometry CRO serving pharma biomarker discovery and clinical trials. Most directly comparable peer given its positioning as a premium scientific CRO focused on immune monitoring and multiplexed proteomics.

Emerging players

  • 10x Genomics: Leading single-cell and spatial biology platform vendor (Chromium, Visium, Xenium) whose services partner ecosystem and direct-to-pharma support competes for the same single-cell/spatial work Sirona Dx services. Treated as an emerging player in services given its primary identity as a tool vendor, but increasingly adjacent to Sirona's offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sirona Dx social profiles

Digital presence

Sirona Dx compliance and trust

Trust signal

Compliance3 records

Sirona Dx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sirona Dx leadership team

Management profile

Number of profiles

Profiles13 records

Sirona Dx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sirona Dx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirona Dx

What does Sirona Dx do?

Sirona Dx is a technical Contract Research Organization that provides spatial biology and single cell multi-omics laboratory services to pharmaceutical and biotechnology companies developing immuno-oncology and immune-based therapeutics. Its offerings span CyTOF/mass cytometry, imaging mass cytometry, multiplex immunofluorescence, spatial transcriptomics, histopathology and immune profiling, delivered through a CLIA/GCLP-accredited laboratory supported by bioinformatics analysis.

Is Sirona Dx a public or private company?

Sirona Dx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sirona Dx founded?

Sirona Dx was founded in 2016. It employs 11 to 50 people.

Where is Sirona Dx based?

Sirona Dx is headquartered in Portland, United States, in the North America region.

How does Sirona Dx make money?

One revenue line is on record: contract Research Services.

Who are Sirona Dx's main competitors?

Broad incumbents on record are ICON plc, Q² Solutions, Eurofins Scientific, Labcorp Drug Development, NeoGenomics Laboratories and Charles River Laboratories. Direct peers are BioAgilytix Labs, Precision for Medicine and CellCarta (formerly Caprion). 10x Genomics is listed as an emerging player.

Does Sirona Dx have an API?

No public API is recorded for Sirona Dx.

What industry is Sirona Dx in?

Sirona Dx's product category is Contract Research Services — Spatial Biology & Multi-Omics. Its primary akta.pro industry code is HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireParhelia and Sirona Dx Partner to Advance the Next Generation of Scalable Spatial Biology ResearchParhelia Biosciences and Sirona Dx announced a strategic partnership to advance spatial biology in translational research, clinical trials, and precision health initiatives. The partnership combines Sirona Dx's technology-agnostic spatial biology expertise with Parhelia's Spatial Station automation platform to improve reproducibility, increase throughput, and reduce costs across spatial biology workflows. The collaboration will support applications including cyclic immunofluorescence and imaging mass cytometry, spanning discovery research through clinical development.Morningstar/C O R R E C T I O N — Parhelia Biosciences Corporation/Parhelia Biosciences and Sirona Dx announced a partnership to combine Sirona's spatial biology expertise with Parhelia's Spatial Station automation platform. The collaboration aims to improve reproducibility, increase throughput, and reduce costs across spatial biology workflows, including cyclic immunofluorescence and imaging mass cytometry.Pharmaceutical TechnologyNucleai, Sirona Dx to provide new proteomics solution for pharma firmsNucleai and Sirona Dx have formed a partnership to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology companies involved in drug development. The collaboration combines Sirona Dx's expertise in assay design and validation with Nucleai's AI-based spatial analytics to bridge the gap between data generation and actionable biological insights. This unified workflow aims to improve biomarker decisions and clinical success rates in fields such as immunology, neuroscience, and oncology.BioSpaceHamamatsu Photonics and Sirona Dx (SDX) Announce Strategic Partnership to Expand Technology Access Program (TAP)Hamamatsu Photonics and Sirona Dx announced a strategic partnership to expand the Technology Access Program, providing customers with access to deep spatial biology expertise in a GCLP/CLIA-accredited lab. The collaboration streamlines evaluation of Hamamatsu's MoxiePlex spatial proteomics technology, removing barriers like sample preparation and bioinformatics analysis.PR NewswireHamamatsu Photonics and Sirona Dx (SDX) Announce Strategic Partnership to Expand Technology Access Program (TAP)Hamamatsu Photonics and Sirona Dx announced a strategic partnership to expand the Technology Access Program, providing customers with access to deep spatial biology expertise in a GCLP/CLIA-accredited lab. The collaboration streamlines evaluation of Hamamatsu's MoxiePlex spatial proteomics technology, removing barriers like sample preparation and bioinformatics analysis.Stock TitanNanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma ResearchersNanoString announced new partnerships with Macrogen, Propath UK, and Sirona Dx to offer CosMx Spatial Molecular Imager technology. These CROs provide global biopharma customers access to spatial biology tools for drug development. The partnerships aim to expand availability of NanoString's spatial imaging platforms.Business Wire BlogNanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma ResearchersNanoString announced new partnerships with Macrogen, Propath UK, and Sirona Dx to offer CosMx Spatial Molecular Imager to biopharma customers. The CROs provide access to the spatial biology tool, with Sirona Dx having acquired multiple systems and Propath UK being the first European CRO to offer a fully managed, GCP-compliant service.NoCamelsNucleai, AI Spatial Biology Startup, Partners with US-Based Sirona DXNucleai, an Israeli AI spatial biology startup, partnered with US-based Sirona DX to discover spatial biomarkers for solid tumors. The collaboration combines Nucleai's AI platform with Sirona DX's contract research services. Nucleai raised $33 million in Series B funding in March, bringing total funding to nearly $50 million.Business Wire BlogNucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid TumorsNucleai and Sirona Dx announced a partnership to use AI spatial analytics and multiplex assay development to discover novel spatial biomarkers in solid tumors. The collaboration aims to identify signatures predicting therapy response and inform treatment decisions. Sirona Dx will serve as a CRO partner for deploying AI-based diagnostic algorithms in biopharma clinical trials.GlobeNewswireSirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic DevelopmentSirona Dx announced Imaging Mass Cytometry services on the Fluidigm Hyperion system to advance biomarker discovery. The technology images up to 37 protein markers from a single scan of FFPE or fresh tissue. Sirona Dx reports positive early response from pharmaceutical partners.